Background:
Premature ovarian insufficiency (POI) is a condition in which women under the age of 40 years have absent or irregular menstrual cycles. POI can cause infertility, signs of menopause, osteoporosis, and other symptoms. Hormone replacement therapy (HRT) is a treatment that gives women extra hormones, such as estrogen and progesterone. HRT works well in adult women. Researchers want to find the most effective doses and regimens for adolescents.
Objective:
To monitor the effects of HRT on adolescents with POI.
Eligibility:
Female adolescents aged 11 to 19 years diagnosed with POI. Healthy volunteers are also needed.
Design:
All participants will have clinic visits every 6 months for 2 years. Each visit may last 2 days. Each visit may include:
Blood and urine tests.
A test of their heart function.
A test to measure the stiffness of their blood vessels. Participants will lie flat with a blood pressure cuff on a leg and a meter on the neck while the cuff inflates.
A test of their grip strength. Participants will squeeze a handheld device as hard as they can.
Two scans to measure bone density. For one, participants will lie on a table while a scanner passes along their body. For the other, participants will sit in a chair and insert their forearm, then their lower leg, into a scanner.
A test to measure skin pigmentation. Participants skin will be touched lightly with a device.
An optional visual exam of the vagina. Some vaginal fluid may also be collected with a cotton swab/cytobrush.
Participants with POI will receive HRT. They will be given estrogen patches and progesterone pills.

Start Date17 Jul 2025

Sponsor / Collaborator-

CTRI/2024/05/068054

/ Not yet recruitingNot ApplicableIIT

To study the utility of Estrogen Receptor and Progesterone Receptor expression as an immunohistochemical predictive markers for tumour behaviour in comparison to histopathological parameters and Tumour, Lymph Node and Metastatic staging in colorectal carcinoma - Nil

Start Date10 Jun 2024

Sponsor / Collaborator-

IRCT20240207060932N1

/ SuspendedPhase 3IIT

Comparison of the effects of Persicaria hydropiper vaginal cream based on coconut oil and sesame oil with conjugated estrogen vaginal cream and placebo on vaginal atrophy and sexual function of postmenopausal women.

Start Date08 Apr 2024

Sponsor / Collaborator-

100 Clinical Results associated with Estrogens, Conjugated

100 Translational Medicine associated with Estrogens, Conjugated

100 Patents (Medical) associated with Estrogens, Conjugated

5,578

Literatures (Medical) associated with Estrogens, Conjugated

31 Dec 2025·JOURNAL OF OBSTETRICS AND GYNAECOLOGY

Comparison of vaginal moisturisers with ultra-low-dose oestriol and lactobacillus vaginal tablets in women with POP who used a pessary: a randomised controlled trial

Article

Author: Saraluck, Apisith ; Chinthakanan, Orawee ; Sarit-Apirak, Sirirat ; Wattanayingcharoenchai, Rujira ; Aimjiraku, Komkrit ; Manonai, Jittima

BACKGROUND:

This study aim to compare the proportion of pessary users reporting satisfaction with ultra-low dose oestriol and Lactobacillus vaginal tablets and vaginal moisturiser.

METHODS:

A randomised-controlled trial enrolled patients who were able to take care, insert, and remove a pessary themselves and did not use any local oestrogen or vaginal moisturiser for 3 months at a tertiary centre. Participants were randomised to receive either vaginal moisturisers or ultra-low-dose oestriol and Lactobacillus vaginal tablets for 2 months. A single-blinded evaluator assessed outcomes. The oestriol group received one vaginal tablet daily for 6 days followed by two tablets weekly for 8 weeks. The moisturiser group received one application every 3 days for 8 weeks. The primary outcome was the proportion of patients reporting high satisfaction, defined as 'very much improved' or 'much improved', using the Thai version of the Patient Global Impression of Improvement (PGI-I) scale. Secondary outcomes were subjective and objective outcomes of vaginal health. Sixty patients were randomised, of whom one did not complete treatment.

RESULTS:

The majority of enrolled participants were postmenopausal women with a mean age of 65.54 years, mean BMI of 25.13 kg/m², and advanced-stage POP. The average duration of pessary use was 12-15 months. Patient satisfaction was not significantly different between the oestriol and moisturiser groups at 4 or 8 weeks (93.10% vs. 96.67%, P = 0.61 and 89.66% vs. 93.33%, P = 0.67, respectively). There were no serious adverse events.

CONCLUSIONS:

Vaginal moisturisers and ultra-low-dose oestriol and Lactobacillus acidophilus vaginal tablets provided high satisfaction in pessary users. Both preparations were comparable in both subjective and objective outcomes.

01 Dec 2025·Current Atherosclerosis Reports

Cardiovascular Risk Associated with Menopause and Menopause Hormone Therapy: A Review and Contemporary Approach to Risk Assessment

Review

Author: Watson, Karol E ; Spertus, Emily ; D'Costa, Zoee ; Press, Marcella Calfon ; Shah, Janki ; Hingorany, Shipra ; Jafari, Lua ; Horwich, Tamara ; Patil, Rajita

Abstract:

Purpose of Review:

Discuss the effects of menopause and menopause hormone therapy (MHT) on cardiovascular risk, and propose a structured, person-centered framework for cardiovascular risk assessment when initiating MHT.

Recent Findings:

The risk of atherosclerotic heart disease accelerates during the menopause transition due to hormonal, metabolic, and vascular changes. Both menopause and MHT affect cardiovascular risk factors (i.e. blood pressure, lipids, insulin resistance) and cardiovascular events (i.e. myocardial infarction and stroke). Early clinical trial evidence demonstrated that oral synthetic MHT, including conjugated equine estrogen (CEE) with medroxyprogesterone acetate (MPA), is associated with increased coronary heart disease and stroke risk, particularly in older, postmenopausal women. Contemporary formulations such as low-dose transdermal estrogen and micronized progesterone have lower cardiovascular risk. A personalized assessment when initiating MHT should consider age, time since menopause, baseline cardiovascular (CV) risk, and choice of MHT formulation. Assessment of baseline CV risk should include a comprehensive review of traditional CV risk factors and consideration of risk-enhancing factors (including female-specific risk factors) and imaging for subclinical atherosclerosis (i.e. coronary artery calcium scoring) to provide a person-centered risk assessment.

Summary:

Menopause is an important period to implement prevention strategies to reduce future incidence CVD. A structured, individualized approach that accounts for the timing, formulation and delivery of MHT can optimize cardiovascular safety. This review provides a framework for personalized decision-making and highlights the need for further research to clarify MHT’s impact on long-term CV outcomes.

Graphical Abstract:

01 Nov 2025·BRAIN BEHAVIOR AND IMMUNITY

Chronic ethanol exposure induces hippocampal neuroinflammation and neuronal damage via the astrocytic RUNX1/TOLLIP/TLR3 pathway

Article

Author: Meng, Fanyue ; Yu, Chenyang ; Guo, Yufu ; Zhang, Qian ; Wang, Changliang ; Lv, Qing ; Zhang, Chaoxu ; Yu, Hao ; Chen, Xiaohuan ; Liu, Hao ; Pei, Jiaxin ; Shen, Hui ; Tie, Jinming ; Wang, Xiaolong

Chronic ethanol exposure (CEE) is acknowledged as a significant risk element for cognitive decline and depression, with NLRP3-related neuroinflammation identified as a crucial mechanism driving depression-like behaviors and cognitive impairment induced by CEE. Here, TLR3 is identified as a priming signal that activates NLRP3 inflammasome triggered by CEE via NF-κB p65 nuclear translocation in astrocytes. CEE-induced neuroinflammation, depressive-like behavior and cognitive impairment are alleviated by downregulation of TLR3. Mechanistically, TOLLIP, a negative regulator of TLR3 pathway, is a target gene of RUNX1, a critical transcription factor associated with inflammation. Therefore, CEE triggers NLRP3-related neuroinflammation, cognitive impairment and depressive-like behavior via RUNX1/TOLLIP/TLR3/p65 axis. Neuronal damage serves as the pathological foundation for mental disorders and is closely associated with neuroinflammatory processes. Most TLR3 in the brain is expressed in the astrocytes. Neuronal damage induced by ethanol exposure is alleviated when inflammatory reactions of astrocytes are suppressed by the inhibition of TLR3 pathway. Thus, the study offers significant insights into CEE-induced neuroinflammation and neuronal damage, as well as the relationship between these two phenomena, and offers potential therapeutic strategies.

News (Medical) associated with Estrogens, Conjugated

14 Oct 2025

·www.drugtopics.com

White House Strikes Deal with Pfizer for Lower Drug Prices, Online DTC Website

Amid ongoing approaches to lower drug prices for US patients, like the Most-Favored-Nation policy, this is another partnership the Trump Administration believes will improve access challenges. The Trump Administration is set to team up with Pfizer in a partnership that would bring lower prices for the manufacturer’s drugs as well as a direct-to-consumer (DTC) website for patients to purchase them, which the White House is naming “TrumpRx.”1 While the rollout of this new partnership is still in its beginning stages, Pfizer is the first drugmaker to provide actionable steps in lowering US drug prices across the board,2 an initiative perpetuated by the signing of the Most-Favored-Nation (MFN) Prescription Drug Pricing Executive Order.3 “It’s a win for American patients, a win for American leadership, and it’s a win for Pfizer because it provides the certainty and stability we need to continue advancing new breakthrough medicines for patients,” said Pfizer spokeswoman Amy Rose, according to The Wall Street Journal.2 Despite early reports of the Pfizer program providing a decrease in drug prices for Medicaid patients, there is potential for savings to reach the pockets of all US patients and consumers as President Trump continues to put pressure on manufacturers. On top of this most recent Pfizer-White House partnership, as well as provisions backed by the MFN policy, the potential impact of pharmaceutical tariffs could add a third layer to the evolution of drug prices in the US. With the new partnership, Pfizer will receive a 3-year grace period on being susceptible to Trump’s pharmaceutical tariffs, which are expected to take effect October 1. “The agreement on lower prices will cover ‘a large majority’ of Pfizer's primary care medicines, along with specialty brand-name drugs, which will be offered at discounts averaging 50% and reaching as high as 85%, a spokesperson for the company said,” according to NBC News.1 Some of the drugs correspondents close to the partnership have named for future price reductions include the menopause medication Duavee (conjugated estrogens/bazedoxifene), Toviaz (fesoterodine fumarate) for treating overactive bladder, and Pfizer’s Eucrisa (crisaborole) skin ointment.4-6 On top of these, and whatever additional drugs that Pfizer already markets, all new drugs that the company introduces will also be sold at lower prices.1 Alongside the announcement of this unprecedented partnership, the administration is set to roll out its “TrumpRx” DTC website for patients across the country to access necessary prescription medications. The website will be fully owned and operated by the US government as well as giving it the federal power to negotiate the prices of DTC drugs themselves.2 The extent of which drugs will be offered and at what type of discounts through the TrumpRx website is currently unknown. There is also uncertainty regarding what patient populations and insurance coverage would be set aside to reap the benefits of these discounts and savings. However, according to Pfizer and White House spokespeople who reported to The Wall Street Journal, the new partnership is projected to benefit as many as 100 million US patients. “Moving forward, the only thing I will accept from drug manufacturers is a commitment that provides American families immediate relief from the vastly inflated drug prices and an end to the free ride of American innovation by European and other developed nations,” said Trump, according to Politico.7 Amid the administration’s ongoing commitment to lower US drug prices, they are looking to get US consumers on a level playing field with consumers in other, developed nations. Hence, the MFN drug policy; this was signed as an executive order in June of this year and plainly states that multiple federal agencies should “take specific actions aimed at compelling drug manufacturers to lower drug prices in the United States in a manner comparable with other ‘developed nations.’”3 From the MFN drug policy to prospective pharmaceutical tariffs and a key partnership between the federal government and a major US drug manufacturer, there is significant movement from the Trump Administration to recorrect the rate of rising drug costs in the US. Many experts in the pharmacy and pharmaceutical industry have expressed disagreement and uncertainty regarding the aforementioned provisions, partnerships, and policies. However, with the continued fight stemming from the administration’s goal to lower drug prices, patients can be hopeful for discounted savings as these programs roll out.1 “President Trump is leveraging the power of the federal government to drastically cut drug prices for everyday Americans,” concluded White House spokesman Kush Desai, according to The Wall Street Journal.2 “Democrats talked the talk for decades about drug prices, but only President Trump is actually walking the walk.” The content above comes from the network. if any infringement, please contact us to modify.

Innovative Drug

10 Oct 2025

·www.einpresswire.com

Estrogen Replacement Therapy Market Forecast and Outlook 2025–2035

Rising demand for advanced hormone therapies positions manufacturers at the forefront of a USD 19.6 billion opportunity by 2035 ROCKVILLE PIKE, MD, UNITED STATES, October 10, 2025 / EINPresswire.com / -- global Estrogen Replacement Therapy (ERT) market is entering a decade of sustained expansion, with revenues projected to grow from USD 11.8 billion in 2025 to nearly USD 19.6 billion by 2035, at a steady compound annual growth rate (CAGR) of 5.2 percent. This 65 percent value increase underscores the growing recognition of menopausal health as a core pillar of women’s healthcare and a strategic investment category for pharmaceutical innovators worldwide. Between 2025 and 2030 alone, the market will add USD 3.4 billion in new revenue, accounting for over 44 percent of the total decade-long expansion. From 2030 to 2035, an additional USD 4.3 billion will be created, supported by the rise of personalized hormone therapies, digital health integration, and next-generation drug delivery systems that enhance safety, adherence, and patient outcomes. Estrogen Replacement Therapy Market Accelerating Demand Driven by Aging Demographics and Clinical Awareness The expansion of the ERT market is anchored in powerful demographic and clinical dynamics. By 2035, more than 1.1 billion women worldwide will be aged 50 and older—a demographic increasingly seeking clinically validated solutions to manage menopausal transitions and long-term estrogen deficiency. Healthcare systems are advancing evidence-based treatment protocols that recommend hormone therapy for moderate to severe menopausal symptoms. As a result, ERT is evolving from a symptom-relief option to a standard component of comprehensive women’s health management, addressing multiple conditions—from hot flashes and mood disturbances to osteoporosis prevention. EstrogenEstrogenOral Tablets Lead Product Innovation with 42.8 Percent Market Share Among product categories, oral tablets continue to dominate the global market with a 42.8 percent share in 2025, supported by their clinical reliability, patient familiarity, and convenience. Within this segment, estradiol tablets (24.7 percent) and conjugated estrogens (18.1 percent) form the cornerstone of modern hormone therapy regimens.Pharmaceutical leaders are investing in improved oral formulations designed for enhanced bioavailability, dose flexibility, and reduced side effects, strengthening patient confidence and long-term adherence. Transdermal patches, topical gels, and vaginal products are also witnessing rapid adoption as part of a multi-modal approach to hormone delivery. These categories are expected to record faster-than-average growth through 2035, driven by innovation in matrix patch systems and bio-identical estrogen formulations. Estrogen Replacement Therapy MarketMenopausal Symptom Management Dominates Applications with 58.7 Percent Share The menopausal symptoms segment remains the market’s growth engine, accounting for 58.7 percent of global demand in 2025. Within this segment, hot flashes (24.3 percent), night sweats (18.9 percent), and mood swings (15.5 percent) comprise the largest sub-applications. The segment’s expansion reflects both the clinical burden of menopause and growing public awareness that comprehensive hormonal therapy delivers measurable improvements in quality of life, emotional well-being, and long-term bone health. Estrogen Replacement Therapy (ERT) market Hospital Pharmacies Lead Distribution with 42.3 Percent Market Share Hospital pharmacies are projected to retain a 42.3 percent share of global distribution in 2025, emphasizing their central role in therapy initiation, dosage management, and safety monitoring. Hospital-based healthcare settings ensure coordinated care through physician oversight, insurance integration, and pharmacovigilance programs—all critical to safe and effective ERT delivery. At the same time, online pharmacies and specialty clinics are gaining traction, particularly in developed markets, offering discreet consultation options and digital prescription management that complement hospital channels. Menopausal Women Drive 67.8 Percent of Market Demand Menopausal women remain the predominant end-user group, representing 67.8 percent of total therapy utilization in 2025. This population’s growing health literacy and proactive management of menopausal symptoms underpin stable, long-term therapy adoption. Increasing physician recommendations and structured healthcare programs are further reinforcing ERT’s position as a trusted, physician-guided treatment option. Estrogen Replacement Therapy (ERT) market Regional Growth Hotspots Highlight Global Opportunity While North America and Europe currently anchor the ERT market, Asia Pacific is emerging as the fastest-growing region, with a CAGR exceeding 7 percent through 2035. India leads globally with 8.7 percent CAGR, fueled by rapid healthcare infrastructure development, growing middle-class access, and rising awareness of women’s health. China, growing at 7.4 percent CAGR, is witnessing an expansion of hospital networks, insurance coverage, and patient education programs. Brazil (6.8 percent), South Korea (6.2 percent), and Japan (5.9 percent) follow closely, reflecting robust public-health programs and clinical maturity. The United States remains the single largest market with 4.8 percent CAGR, supported by evidence-based clinical practices, insurance coverage, and a highly developed women’s healthcare ecosystem. Estrogen Replacement Therapy (ERT) market Personalized Medicine and Digital Health: The Next Frontier The ERT industry is entering a transformative phase where personalized medicine and digital health integration redefine patient engagement. Leading pharmaceutical manufacturers are investing in AI-driven hormone dosing algorithms, biomarker-based patient selection, and wearable-linked symptom tracking platforms that enable physicians to fine-tune therapy with unprecedented precision.Remote monitoring and telehealth are expected to become standard components of post-prescription management by 2030, ensuring higher adherence and better long-term outcomes. Competitive Landscape: Innovation, Safety, and Accessibility The ERT market remains moderately consolidated, led by Pfizer Inc. (18.7 percent), Bayer AG, Novartis AG, Merck & Co. Inc., and AbbVie Inc., alongside Teva Pharmaceutical Industries, Mylan N.V., TherapeuticsMD, and Noven Pharmaceuticals.Manufacturers are focusing on bio-identical formulations, micro-dose therapies, and next-generation delivery systems that combine efficacy with improved safety profiles.Strategic collaborations between pharma giants, research institutions, and healthcare providers are accelerating clinical validation and expanding therapy accessibility across developed and emerging markets. Request Discount https://www.factmr.com/connectus/sample?flag=S&rep_id=11192 Buy Now This Report at USD(2900): https://www.factmr.com/checkout/11192 Estrogen Replacement Therapy (ERT) Market Outlook: 2035 and Beyond As global attention shifts toward proactive and preventive healthcare for women, estrogen replacement therapy will continue to play a central role in enhancing quality of life, longevity, and holistic well-being. The market’s evolution toward personalized, tech-enabled, and evidence-based care opens new frontiers for manufacturers to innovate, expand, and differentiate their portfolios. Check out More Related Studies Published by Fact.MR: Conjugated Estrogen Market https://www.factmr.com/report/2289/conjugated-estrogen-market Hip Replacement Market https://www.factmr.com/report/hip-replacement-market Hormone Replacement Therapy Market https://www.factmr.com/report/2224/hormone-replacement-therapy-market S. N. Jha Fact.MR +1 628-251-1583 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

01 Oct 2025

·www.pharmaceutical-technology.com

Pfizer shakes hands with White House on drug discounts under MFN programme

A press conference was held in the Oval Office to announce the deal between Pfizer and the US Government. Image credit: Win McNamee / Staff via Getty Images. Pfizer is the first in what could be a string of pharmaceutical companies to come to an agreement with the White House to reduce US drug prices. As part of President Trump’s Most Favored Nation (MFN) policy , the company agreed to ensure that US patients are paying less for prescription medicines, with primary care treatments and some select speciality brands set to be offered at savings that will range as high as 85% and an average of 50%. The MFN policy has been set up by Trump’s administration to tie drug prices in the US to those paid elsewhere in the world. These savings will be accessible through both Medicaid and the federal direct purchasing platform TrumpRx.gov. It was also announced that all new medications from Pfizer will be sold at MFN levels. In a 30 September press conference, Trump said: “For many years, Americans have paid the highest prices anywhere in the world for prescription drugs. The major reason is that American consumers have been subsidising research and development costs for the entire planet. They put all of that on us, and yet they were the beneficiaries, so that is being changed as of today.” Discounts, shown on a poster during the press conference, include an 80% discount on Eucrisa (crisaborole), an 85% discount on Duavee (conjugated estrogens/bazedoxifene), 50% off Zavzpret (zavegepant), and 40% off Xeljanz (tofacitinib). GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence The agreement includes a three-year grace period that excludes Pfizer from facing tariffs, as long as the promised $70bn investment into US manufacturing goes ahead. In the press conference, Pfizer CEO Albert Bourla said: “This is a historic day – we are turning the tide and reversing an unfair situation. For years, other rich nations have refused to pay their fair share for medical innovation. This is changing today with this agreement.” While Pfizer is the first to have come to this agreement with the US Government, Trump said that agreements with other pharmaceutical companies could happen in the next few weeks. GlobalData research analyst Cyrus Fan said: “The Trump administration has said the Pfizer deal is the first in a series of deals it intends to secure for the US. This implies more companies will agree to MFN pricing. It is also clear that the Trump administration is easing implementation of MFN by introducing IRP in Medicaid first, leaving room for expansion in the future.” GlobalData is the parent company of Clinical Trials Arena. For those who do not agree to increase the US manufacturing presence and make price agreements with the federal government, President Trump has threatened a 100% tariff on pharmaceutical goods. In a post on his social media network, TruthSocial, on 25 September, President Trump said: “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America. ‘IS BUILDING’ will be defined as, ‘breaking ground’ and/or ‘under construction.’ There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.” This all comes amid a potential government shutdown, with Democrats accusing the Republicans of approving cuts to the Medicaid programme and other health safety nets that could leave millions of US citizens uninsured in the next ten years. Editor’s note: Comments from GlobalData analyst Cyrus Fan have been added. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

100 Deals associated with Estrogens, Conjugated

External Link

KEGG	Wiki	ATC	Drug Bank
D04070	Estrogens, Conjugated	G03CA57	DB00286

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Oestrogen deficiency	Australia	Pfizer Australia Pty Ltd.	28 May 2012
Dyspareunia	United States	Wyeth Pharmaceuticals LLC	07 Nov 2008
Osteoporosis	United States	Wyeth Pharmaceuticals LLC	16 Jul 2003
Breast Cancer	United States	Wyeth Pharmaceuticals LLC	24 Apr 2003
Hypoestrogenism	United States	Wyeth Pharmaceuticals LLC	24 Apr 2003
Prostatic Cancer	United States	Wyeth Pharmaceuticals LLC	24 Apr 2003
Vasomotor symptom	United States	Wyeth Pharmaceuticals LLC	24 Apr 2003
Vulvovaginal atrophy	China	Wyeth Canada ULC	07 Mar 2001
Atrophic Vaginitis	United States	Wyeth Pharmaceuticals LLC	16 Oct 1978
Atrophy	United States	Ayerst-Wyeth Pharmaceuticals, Inc.	16 Oct 1978
Vulvar Lichen Sclerosus	United States	Wyeth Pharmaceuticals LLC	16 Oct 1978
Andropause	Japan	Pfizer Japan, Inc.	15 Apr 1964
Metrorrhagia	Japan	Pfizer Japan, Inc.	15 Apr 1964
Ovarian Diseases	Japan	Pfizer Japan, Inc.	15 Apr 1964
Vaginitis	Japan	Pfizer Japan, Inc.	15 Apr 1964
Endocrine System Diseases	United States	Wyeth Pharmaceuticals LLC	18 Dec 1956
Osteoporosis, Postmenopausal	United States	Wyeth Pharmaceuticals LLC	08 May 1942
Vascular Diseases	United States	Ayerst-Wyeth Pharmaceuticals, Inc.	07 May 1942

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Menopausal symptoms	Phase 3	United States	Teva Branded Pharmaceutical Products R&D, Inc.	01 Aug 2006
Parkinson Disease	Phase 2	United States	Wyeth AB	01 Oct 2003
Amenorrhea	Phase 2	-	Abbott Laboratories	01 Sep 2000
Primary Ovarian Insufficiency	Phase 1	Japan	Pfizer Inc.	01 Oct 2011
Hot Flashes	Phase 1	United States	Wyeth AB	01 Jun 2008
Pelvic Organ Prolapse	Clinical	United States	Pfizer Inc.	01 May 2012
Uterine Prolapse	Clinical	United States	Pfizer Inc.	01 May 2012
Vaginal Diseases	IND Approval	China	Xinjiang Xinziyuan Biopharmaceutical Co., Ltd	22 Oct 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01648751 (CTgov)	Not Applicable	Pelvic Organ Prolapse \| Uterine Prolapse	21	Vaginal estrogen (Vaginal Estrogen)	fmxmdelvsj(jtjuwmwnwa) = lfxkbzcwxc vkpbjweqmr (lqlwsodqev, qgcudltfuw - npygwjanlr) View more	-	19 Sep 2024
				Placebo (Placebo Cream)	fmxmdelvsj(jtjuwmwnwa) = pjrevgrbjg vkpbjweqmr (lqlwsodqev, rafcpjntkx - ktorfcaoyb) View more
NCT03943823 (CTgov)	Phase 4	Vaginal Discharge \| Bacterial Vaginosis	4	Premarin+Estrace (Estrogen Vaginal Cream)	echhntauct(dbgbdhrmee) = hplxwijvqo dqghvnhcdg (vagttdxixf, 0.70) View more	-	01 Mar 2023
				Trimo-San (Trimo-San Vaginal Gel)	echhntauct(dbgbdhrmee) = blnpjsawoa dqghvnhcdg (vagttdxixf, 0) View more
NCT01958073 (VESPR, CTgov)	Phase 4	Urinary Tract Infections	35	Placebo (Placebo)	loahgzhucw = uebqnlbnam bvlwmyqofj (sknvoioxzx, fucdrhtjfj - lxslvwxugm) View more	-	21 Sep 2020
				Conjugated Estrogen Vaginal Cream (Conjugated Estrogen Vaginal Cream)	szjwtplace = znbpihqepo enzinamwzo (csbcuuguwz, jdjoknpbgo - pknzlqljwn) View more
NCT00973102 (RESCUE-Shock \| RESCUE - Shock, CTgov)	Phase 2	Shock, Hemorrhagic \| Shock	50	Premarin IV (Premarin IV)	mlpehrajhl = ncybzblxeu oukskdlqzk (aqhqetwrut, vyekwnogrl - wfejfvgcre) View more	-	19 Mar 2020
				Placebo (Placebo)	mlpehrajhl = wjgoogwink oukskdlqzk (aqhqetwrut, ivdtldifjo - qsujopifte) View more
NCT00973674 (RESCUE-TBI, CTgov)	Phase 2	Brain Injuries, Traumatic	50	Premarin IV (Premarin IV)	tajyafwtfz = ecmofwiwom offbyaoguo (yexbqwaalw, skkyhggyqq - qkelkhplrk) View more	-	12 Nov 2019
				Placebo (Placebo)	tajyafwtfz = heaukitgzn offbyaoguo (yexbqwaalw, kewnvcowbd - sqqcgmmiki) View more
NCT01268046 (CTgov)	Phase 1/2	Amnesia	38	Estradiol+transderman estrogen patch (Young Postmenopausal Women - Estrogen)	iltrhdsics(yfxqqxszid) = pujepxyvkg rsotvgzmtb (ytxpvwsbsq, 164.3) View more	-	22 Aug 2018
				Estradiol+transderman estrogen patch (Older Postmenopausal Women - Estrogen)	iltrhdsics(yfxqqxszid) = mmibllezlr rsotvgzmtb (ytxpvwsbsq, 90.1) View more
NCT00604825 (CTgov)	Phase 2	Menopausal symptoms \| Hot Flashes \| Vasomotor symptom ... View more	356	Other: Placebo	jrnlbhjdjv = symyvrptmg zfvxtsphaj (bfeaqbbbpd, pxqsjaezhz - fejudiwbtx) View more	-	03 Oct 2017
NCT00386022 (CTgov)	Phase 2/3	-	19	GnRH+Estrogen patch (Young Postmenopausal Women)	xautgujeqc(eowpwkyrst) = lwzqoywrcq ngcvjwvawe (cmxvuctbhe, 1.9) View more	-	13 Apr 2017
				GnRH+Estrogen patch (Older Postmenopausal Women)	xautgujeqc(eowpwkyrst) = cjgqpqqios ngcvjwvawe (cmxvuctbhe, 1.0) View more
NCT02524561 (KEEPS MDBHAS, CTgov)	Not Applicable	Breast Diseases	517	Placebo patch+Active Progesterone+CEE pill (CEE Pill, Active Progesterone)	metunybhpj = dppdiulzxp uemjefsnwd (smzupveqai, lcxelovnog - owwgiztbld) View more	-	08 Mar 2017
				Placebo tablet+Active Progesterone+Estradiol patch (Estradiol Patch, Active Progesterone)	metunybhpj = aagueptmyp uemjefsnwd (smzupveqai, krcpjtfdfz - okqaroidtj) View more
NCT01023178 (CTgov)	Not Applicable	Ovarian Insufficiency \| Primary Ovarian Insufficiency	20	17Beta Estradiol (Transdermal 17Beta Estradiol)	ivgbbkvoyq(ynkirjvgmp) = ivyixggvtj gfdneyhlyq (kdpzewinyw, 19) View more	-	20 Jan 2017
				Progesterone+Conjugated estrogens (Oral Conjugated Equine Estrogen)	ivgbbkvoyq(ynkirjvgmp) = ficfcbagfx gfdneyhlyq (kdpzewinyw, 5) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis